Brain, Vol. 122, No. 3, 449-460,
March 1999
© 1999 Oxford University Press
Article |
The distribution of ganglioside-like moieties in peripheral nerves
1 Departments of Neurology and 2 Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, 3 National Center for Microscopy and Imaging Research at San Diego and 4 Department of Neurosciences, University of California San Diego, La Jolla, California, USA
Correspondence to:
Dr Kazim Sheikh, Department of Neurology, Johns Hopkins University, Pathology Building 509, 600 N. Wolfe Street, Baltimore, MD 21287, USA E-mail: ksheikh{at}welchlink.welch.jhu.edu
GM1 ganglioside has been implicated as a target of immune attack in some diseases of the peripheral nervous system. Anti-GM1 ganglioside antibodies are associated with certain acquired immune-mediated neuropathies. It is not clear how anti-GM1 antibodies cause nerve dysfunction and injury; however, sodium and/or potassium ion channel dysfunction at the node of Ranvier has been implicated. To gain insight into the pathogenesis of these neuropathies, we examined the distribution of GM1 ganglioside and Gal(ß1–3)GalNAc moieties in nerve fibres and their relationship to voltage-gated sodium and potassium (Kv1.1, 1.5) channels at the nodes of Ranvier in peripheral nerves from human, rat and dystrophic mice. Gal(ß1–3)GalNAc moieties were localized via the binding of cholera toxin and peanut agglutinin. As a control for the specificity of these findings, we compared the distribution of GM1 moieties to that of the ganglioside GT1b. Our study provides definitive evidence for the presence of Gal(ß1–3)GalNAc bearing moieties on the axolemmal surface of mature myelinated fibres and on Schwann cells. Gal(ß1–3)GalNAc binding sites did not have an obligatory co-localization with voltage-gated sodium channels or the potassium ion channels Kv1.1 and Kv1.5 and are thus not likely carried by these ion channels. In contrast with Gal(ß1–3)GalNAc, GT1b-like moieties are restricted to the axolemma.
Gal(ß1–3)GalNAc moieties; ani-GMI antibodies; voltage-gated sodium and potassium channels; acquired immune neuropathies; cholera toxin
CT = cholera toxin B subunit; DAB = 3,3 diaminobenzidine tetrahydrochloride; FITC = fluoroisothiocyanate; PNA = peanut agglutinin; TTC = tetanus toxin fragment C
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Kaida, T. Ariga, and R. K Yu Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review Glycobiology, July 1, 2009; 19(7): 676 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaida, M. Sonoo, G. Ogawa, K. Kamakura, M. Ueda-Sada, M. Arita, K. Motoyoshi, and S. Kusunoki GM1/GalNAc-GD1a complex: A target for pure motor Guillain-Barre syndrome Neurology, November 18, 2008; 71(21): 1683 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. H. Lopez, G. Zhang, M. A. Bianchet, R. L. Schnaar, and K. A. Sheikh Structural requirements of anti-GD1a antibodies determine their target specificity Brain, July 1, 2008; 131(7): 1926 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shavit, O. Beilin, A. D. Korczyn, C. Sylantiev, R. Aronovich, V. E. Drory, D. Gurwitz, I. Horresh, R. Bar-Shavit, E. Peles, et al. Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block Brain, April 1, 2008; 131(4): 1113 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Susuki, M. N. Rasband, K. Tohyama, K. Koibuchi, S. Okamoto, K. Funakoshi, K. Hirata, H. Baba, and N. Yuki Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Sodium Channel Clusters in Peripheral Motor Nerve Fibers J. Neurosci., April 11, 2007; 27(15): 3956 - 3967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T H Van Asseldonk, L H Van den Berg, S Kalmijn, R M Van den Berg-Vos, C H Polman, J H J Wokke, and H Franssen Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Marconi, M Acler, L Lovato, L De Toni, E Tedeschi, E Anghileri, S Romito, C Cordioli, and B Bonetti Anti-GD2-like IgM autoreactivity in multiple sclerosis patients Multiple Sclerosis, June 1, 2006; 12(3): 302 - 308. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Yuki, K. Susuki, M. Koga, Y. Nishimoto, M. Odaka, K. Hirata, K. Taguchi, T. Miyatake, K. Furukawa, T. Kobata, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome PNAS, August 3, 2004; 101(31): 11404 - 11409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nishimoto, M. Koga, M. Kamijo, K. Hirata, and N. Yuki Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration Neurology, June 8, 2004; 62(11): 1939 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Susuki, M. Odaka, M. Mori, K. Hirata, and N. Yuki Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry Neurology, March 23, 2004; 62(6): 949 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaida, S. Kusunoki, K. Kamakura, K. Motoyoshi, and I. Kanazawa GalNAc-GD1a in human peripheral nerve: Target sites of anti-ganglioside antibody Neurology, August 26, 2003; 61(4): 465 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Willison and N. Yuki Peripheral neuropathies and anti-glycolipid antibodies Brain, December 1, 2002; 125(12): 2591 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gong, Y. Tagawa, M. P. T. Lunn, W. Laroy, M. Heffer-Lauc, C. Y. Li, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh Localization of major gangliosides in the PNS: implications for immune neuropathies Brain, November 1, 2002; 125(11): 2491 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.D.M. Hadden, H. Karch, H.-P. Hartung, J. Zielasek, B. Weissbrich, J. Schubert, A. Weishaupt, D.R. Cornblath, A.V. Swan, R.A.C. Hughes, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome Neurology, March 27, 2001; 56(6): 758 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Asbury New Concepts of Guillain-Barre Syndrome J Child Neurol, March 1, 2000; 15(3): 183 - 191. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Sheikh, J. Sun, Y. Liu, H. Kawai, T. O. Crawford, R. L. Proia, J. W. Griffin, and R. L. Schnaar Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects PNAS, June 22, 1999; 96(13): 7532 - 7537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kaji and J. Kimura Facts and fallacies on anti-GM1 antibodies: physiology of motor neuropathies Brain, May 1, 1999; 122(5): 797 - 798. [Full Text] [PDF]
|
|